Shopping Cart 0
Cart Subtotal
USD 0

Imprimis Pharmaceuticals Inc (IMMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie's disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.

Imprimis Pharmaceuticals Inc (IMMY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13

Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14

Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15

Licensing Agreements 16

Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16

Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17

Imprimis Pharma Enters into License Agreement with Urigen Pharma 18

Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20

Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21

Equity Offering 22

Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22

Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23

Imprimis Pharma Files Registration Statement for Public Offering of Shares 24

Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25

Imprimis Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD12 Million 26

Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28

Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 11.1 Million 29

Imprimis Pharma Completes Private Placement Of Units For USD 8 Million 30

Debt Offering 31

Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31

Asset Transactions 32

Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32

Acquisition 33

Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33

Imprimis Pharma Acquires South Coast Specialty Compounding 34

Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For USD 4 Million 35

Imprimis Pharmaceuticals Inc-Key Competitors 36

Imprimis Pharmaceuticals Inc-Key Employees 37

Imprimis Pharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Strategy And Business Planning 40

Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary 40

Financial Announcements 41

Aug 06, 2018: Imprimis Pharmaceuticals announces second quarter 2018 results 41

May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results 42

Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results 43

Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results 44

Aug 10, 2017: Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results 46

May 10, 2017: Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results 47

Mar 21, 2017: Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results 48

Legal and Regulatory 50

Jan 24, 2018: Imprimis Pharmaceuticals Receives DEA Manufacturer Controlled Substance Registration Certificate 50

Sep 14, 2017: FDA Curcumin Investigation Supports Imprimis Statement 51

Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 52

Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber's Choice and Sincerus Florida 53

Product News 54

Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis 54

Other Significant Developments 55

Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations 55

Jul 20, 2017: Imprimis Pharmaceuticals Announces USD 16 Million Debt Facility with SWK Holdings 56

Feb 16, 2017: Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13

Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14

Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15

Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16

Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17

Imprimis Pharma Enters into License Agreement with Urigen Pharma 18

Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20

Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21

Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22

Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23

Imprimis Pharma Files Registration Statement for Public Offering of Shares 24

Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25

Imprimis Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD12 Million 26

Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28

Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 11.1 Million 29

Imprimis Pharma Completes Private Placement Of Units For USD 8 Million 30

Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31

Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32

Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33

Imprimis Pharma Acquires South Coast Specialty Compounding 34

Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For USD 4 Million 35

Imprimis Pharmaceuticals Inc, Key Competitors 36

Imprimis Pharmaceuticals Inc, Key Employees 37

Imprimis Pharmaceuticals Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Imprimis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie's disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.

Imprimis Pharmaceuticals Inc (IMMY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13

Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14

Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15

Licensing Agreements 16

Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16

Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17

Imprimis Pharma Enters into License Agreement with Urigen Pharma 18

Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20

Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21

Equity Offering 22

Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22

Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23

Imprimis Pharma Files Registration Statement for Public Offering of Shares 24

Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25

Imprimis Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD12 Million 26

Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28

Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 11.1 Million 29

Imprimis Pharma Completes Private Placement Of Units For USD 8 Million 30

Debt Offering 31

Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31

Asset Transactions 32

Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32

Acquisition 33

Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33

Imprimis Pharma Acquires South Coast Specialty Compounding 34

Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For USD 4 Million 35

Imprimis Pharmaceuticals Inc-Key Competitors 36

Imprimis Pharmaceuticals Inc-Key Employees 37

Imprimis Pharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Strategy And Business Planning 40

Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary 40

Financial Announcements 41

Aug 06, 2018: Imprimis Pharmaceuticals announces second quarter 2018 results 41

May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results 42

Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results 43

Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results 44

Aug 10, 2017: Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results 46

May 10, 2017: Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results 47

Mar 21, 2017: Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results 48

Legal and Regulatory 50

Jan 24, 2018: Imprimis Pharmaceuticals Receives DEA Manufacturer Controlled Substance Registration Certificate 50

Sep 14, 2017: FDA Curcumin Investigation Supports Imprimis Statement 51

Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 52

Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber's Choice and Sincerus Florida 53

Product News 54

Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis 54

Other Significant Developments 55

Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations 55

Jul 20, 2017: Imprimis Pharmaceuticals Announces USD 16 Million Debt Facility with SWK Holdings 56

Feb 16, 2017: Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Imprimis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13

Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14

Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15

Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16

Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17

Imprimis Pharma Enters into License Agreement with Urigen Pharma 18

Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20

Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21

Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22

Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23

Imprimis Pharma Files Registration Statement for Public Offering of Shares 24

Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25

Imprimis Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD12 Million 26

Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28

Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 11.1 Million 29

Imprimis Pharma Completes Private Placement Of Units For USD 8 Million 30

Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31

Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32

Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33

Imprimis Pharma Acquires South Coast Specialty Compounding 34

Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For USD 4 Million 35

Imprimis Pharmaceuticals Inc, Key Competitors 36

Imprimis Pharmaceuticals Inc, Key Employees 37

Imprimis Pharmaceuticals Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Imprimis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.